

## Publisher's Note

An Update has Arrived in Your Library for:

<b>Please circulate this notice to anyone in your office who may be interested in this publication.</b> <i>Distribution List</i>
<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>
<input type="checkbox"/>

### **DRUG AND HEALTH PRODUCTS LAW IN CANADA**

**Mathieu Gagné**

**Release No. 1, October 2024**

This book provides a comprehensive guide to the legal and regulatory regimes—provincial and federal—governing the manufacture and sale of drugs and health products in Canada. It is a must-have resource for anyone involved in any aspect of the development, manufacture and distribution of drugs in Canada, and for lawyers who represent both those in the industry and those wishing to challenge industry practice or procedure. Written by one of Canada's experts in the field.

This release features updates to Chapter 8 (Federal Penal Law), Chapter 14 (Prescription Drug Insurance Plans in Canada – Canada) and Appendix WP (Words and Phrases).

---

**THOMSON REUTERS®**

**Customer Support**

1-416-609-3800 (Toronto & International)

1-800-387-5164 (Toll Free Canada & U.S.)

E-mail [CustomerSupport.LegalTaxCanada@TR.com](mailto:CustomerSupport.LegalTaxCanada@TR.com)

This publisher's note may be scanned electronically and photocopied for the purpose of circulating copies within your organization.

**Highlights:**

- Significant updates have been made to the commentary, legislation and case law in Chapter 8 (Federal Penal Law) and Chapter 14 (Prescription Drug Insurance Plans in Canada – Canada). For example, Chapter 8 has been updated to include discussion of Health Canada’s 2023 *Guidance on distinction between advertising and other activities for health products* and Chapter 14 has been updated to include discussion of Bill C-64: *An Act respecting pharmacare*, a bill tabled by the Federal Parliament in February of 2024.
- **Appendix WP—Words and Phrases**—This appendix has been updated to 18 July 2024 in this release and includes updates from several jurisdictions, for example, the Ontario Court of Appeal defined Valsartan in the case of *Palmer v. Teva Canada Limited*, 2024 ONCA 220, 2024 CarswellOnt 4329:

Valsartan is an antihypertensive drug prescribed to regulate blood pressure and prevent heart failure and stroke. Since about 2011, valsartan has been “off patent” and manufactured by generic pharmaceutical companies like the defendants.